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Alzheimer’s disease is an irreversible, progressive brain disorder that slowly destroys memory and cognition skills. 
Dysfunction of acetylcholine containing neurons in the brain contributes substantially to the cognitive decline observed in 
Alzheimer's disease. Hence, our focus is to synthesize cholinesterase inhibitors. A series (22 compounds) of 6- and 9-
substituted derivatives of 2,3,4,9-tetrahydro-1H-carbazole have been prepared and in vitro evaluated for acetylcholinesterase 
(AChE) and butyrylcholinesterase (BChE) inhibition by Ellman’s method. By comparing selectivity with standard drug 
donepezil, amino derivative 3, methylamino derivative 4 and butyl nitro derivative 17 have been found to be selective AChE 
inhibitors. Borsche-Drechsel cyclization reaction has been carried out to synthesize 2,3,4,9-tetrahydrocarbazole ring 
followed by nitration, reduction and derivative synthesis. 
Keywords: Alzheimer’s disease, acetylcholinesterase (AChE), Borsche-Drechsel cyclization reaction, donepzil, 2,3,4,9-
tetrahydro-1H-carbazoles 
Alzheimer’s disease (AD) is irreversible, progressive 
brain disorder related to changes in nerve cells that 
result in the death of brain cells delineated by an 
incessantly decline in cognitive performance 
accompanied by behavioural and psychological 
syndromes, such as depression and psychosis1. 
Worldwide, about 50 million people are believed to 
be living with Alzheimer's disease. These alarming 
rates could exceed 152 million by 2050 2. Currently 
there are many hypotheses that describe molecular 
mechanisms which may play a role in the 
development of AD. The two of main hypotheses are 
the ‘‘cholinergic hypothesis’’, which is based on 
neurochemical findings that suggest a discernible 
decrease in acetylcholine containing neurons in AD 
brain. The second hypothesis is the ‘‘amyloid 
hypothesis’’, which revealed intraneuronal deposits of 
tau-protein derived neurofibrillary tangles and 
extracellular deposits of β-amyloid protein in AD 
brains. These deposits are present in ‘‘senile 
plaques’’, which was confirmed during earlier 
diagnosis of AD. The neurochemical correlates of 
these clinical manifestations appear to involve in 
multiple neurotransmitter pathways dysfunctions3,4. 
The main stress of the cholinergic hypothesis  
is on the enhanced activity of the enzyme 
acetylcholinesterase. In Alzheimer’s disease 
individuals, the activity of the acetylcholinesterase 
increases and leads to augmented breakdown of the 
neurotransmitter acetylcholine and causes the 
plummeting of the acetylcholine level in brain. Other 
relation between the enzyme and AD has been the 
partial involvement of the enzyme in the formation of 
amyloids plaques and neurfibrillary tangles. It has 
been shown that acetylcholinesterase (AChE) 
promotes the aggregation of β-amyloid peptide 
fragments by forming a complex with the growing 
fibrils5. These complexes have been shown to be more 
cytotoxic than β-amyloid fibrils alone. The beneficial 
role of cholinergic manipulation is presumably 
through the amplification of ACh agonist actions by 
inhibiting its metabolizing enzymes i.e. AChE 
inhibition. It has been mediated by the effects of 
direct agonists, both muscarinic and nicotinic. 
Butyrylcholinesterase (BChE) is abundant in plasma 
and interstitial fluids of peripheral tissues,and it’s 
inhibition exhibits peripheral side effects like 
salivation and gastrointestinal complaints6. Peripheral 




anionic site (PAS) of AChE is involved in converting 
soluble β-amyloid to insoluble amyloid7. Selectivity 
for acetylcholinesterase is desired for Alzheimer’s 
treatment drug. Four cholinesterase inhibitors, 
Tacrine(I), Donepezil (II), Rivastigmine(III) and 
Galantamine(IV) (Figure 1) have been used for 
treating symptomatic treatment of AD8. 
Literature survey shows that 9H-carbazole 
drivatives9 and 2,3,4,4a-yetrahydro-1H-carbazoles10 
have anti-cholinesterase activity. Hence, tetrahydro-
carbazole is chosen as a central motif and substituted 
the basic moiety at 6 and 9 position. Therefore, aim 
of present investigation is to focus on the synthesis 
and evaluation of 2,3,4,9-tetrahydrocarbazole 
derivatives as AChE inhibitors. Donepezil is selected 
as standard drug as italso binds on PAS of AChE11. 
 
Results and Discussion 
 
Chemistry 
Synthesis of tetrahydrocarbazole (compound 1) as 
shown in Scheme I is Borsche-Drechsel cyclization 
reaction which involves the condensation of 
phenylhydrazine with cyclohexanone in presence  
of glacial acetic acid12,13. Nitration of 
tetrahydrocarbazole involves reaction with sodium 
nitrate and sulphuric acid14. Reduction of compound 2 
involves reaction with sodium hydroxide and zinc 
dust15. Synthesis of sulphonamide derivatives 
compounds 11, 12, 13, 19 and 20 is modified 
Schotten Baumann type reaction which involves the 
reaction of compound 2 and 3 with alkyl/aryl 
sulphonyl chlorides in presence of pyridine16. Third 
type of reaction is nucleophilic substitution of 
alkyl/aryl halides which involves reaction of 
compound 2 and 3 with alkyl halides in presence of 
N,N-Dimethylformamide and potassium carbonate17 
to yield compounds 4-10, 14-18, 21, 22as indicated in 
Scheme I. 
 
In-vitro AChE and BChE inhibitory activity 
The 2,3,4,9-tetrahydro-1H-carbazole and its 
derivatives are evaluated for AChE and BChE 
inhibition by Ellman’s method18,19 using donepezil as 
standard drug. All compounds showed AChE and 
BChE inhibitory activitiesas shown in Table I. 
Compound 3, 4 and 17 were found to be more 
selective towards AChE inhibition. Increase in alkyl 
chain length at 6-amino tetrahydrocarbaole and 6-
nitro tetrahydrocarbaole derivativeslead to decrease in 
AChE selectivity. Furthermore, introduction of bulky 
group like benzyl, methane sulfonyl, benenesulfonyl 
and tosyl group of both 6-aminotetrahydrocarbaole 




The structure of the E20-TcAChE complex (1EVE) 
has 2.5A° resolution. The peripheral anionic site of 
acetylcholinestrase is chosen for docking analysis. 
The peripheral anionic site lies on the surface of 
acetylcholinesterase, approximately 20A° distant from 
the active site. It mainly consist of five residues 
Tyr70(72), Asp72(74), Tyr121(124), Trp279(286), 
and Tyr334(341) clustered around the entrance to the 
active site gorge. Torpedo numbering  is  given   first,  
 
 
Figure 1 — Structures of compounds I–IV used in AD treatment 







Scheme I — Reagents and conditions: (a) Cyclohexanone, Glacial acetic acid, reflux, 5 min.; (b) Sodium nitrate in sulfuric acid, stirring 
1.5 h; (c) Zinc, Sodum hydroxide, reflux, 1 h; (d) N,N-dimethyl formamide, potassium carbonate, reflux, 24 h, alkylbromides: CH3Br (4), 
C2H5Br (5), C3H7Br (6) C4H9Br (7), C5H11Br (8), C6H13Br (9), C7H15Br (10); (e) Dry pyridine, reflux, 30 min., alkyl chloride, aryl 
chlorides: C7H8SO2Cl (11), CH3SO2Cl (12), C6H5SO2Cl (13), C6H5CH2Cl (14); (f) N,N-dimethyl formamide, potassium carbonate, 
reflux, 24 h, alkyl bromides: C2H5Br (15), C3H7Br (16) C4H9Br (17), C5H11Br (18); (g) Dry pyridine, reflux, 30 min., alkyl chloride, aryl 
chlorides: C7H8SO2Cl (19), CH3SO2Cl (20), C7H5OCl (21), C6H5CH2Cl (22). 
 
Table I — Acetylcholinesterase and butyrylcholinesterase inhibitory activities of compounds 1-22 
Compd IC50 (µM) AChE IC50 (µM) BChE 
Donepezil 0.0427 ± 0.078 1.216 ± 0.045 
1 2.02 ± 0.479 8.97 ± 0.450 
2 2.68 ± 0.652 7.31 ± 0.890 
3 0.0388 ± 0.008 0.482 ± 0.180 
4 0.0324 ± 0.004 2.553 ± 0.770 
5 1.94 ± 0.400 6.04 ± 0.610 
6 4.19 ± 0.630 14.38 ± 0.150 
7 4.50 ± 0.560 11.21 ± 0.780 
8 5.24 ± 0.873 13.29 ± 0.520 
9 4.88 ± 0.578 12.05 ± 0.320 
10 12.43 ± 0.698 9.16 ± 0.310 
11 6.90 ± 0.810 7.63 ± 0.880 
12 8.41 ± 0.566 9.03 ± 0.650 
13 13.64 ± 0.829 11.98 ± 0.300 
14 2.78 ± 0.326 10.0 ± 0.800 
15 1.64 ± 0.528 1.82 ± 0.326 
16 2.21 ± 0.823 1.79 ± 0.681 
17 0.203 ± 0.020 4.13 ± 0.268 
18 2.27 ± 0.400 7.82 ± 0.427 
19 3.63 ± 0.946 4.68 ± 0.589 
20 5.75 ± 0.750 6.14 ± 0.457 
21 11.28 ± 0.622 13.24 ± 0.482 
22 5.40 ± 0.382 9.45 ± 0.726 
 




followed by mammalian numbering in brackets20. All 
the compounds fit into the PAS gorge as shown in 
Figure 2 and its interaction with residues is 
summarised in Table II. Further, most active (most 
stable based on energy) compound 9 overlays on 
donepezil and interact with most of residues are 
indicated in Figure 3. 
For any ligand to bind to PAS of AChE interaction 
with Tyr70(72), Tyr121(124) and Trp279(286) is 
critical. All compound except 1 and 3 show 
interaction with Trp279. Hence all compounds are 
selective towards AChE than butyrylcholinesterase.  
Experimentally compound 3, 4 and 17 are more 
active and selective towards AChE amongst the 
 
 
Figure 2 — Figure representing all the ligands together fit in the
PAS gorge cavity 
Table II — Table showing total energy and interacting residue of compounds 1-22 
Compd Total energy Interaction Residues 
Donepezil -120.7 Tyr121, Tyr70, Asp72, Trp279, Tyr334 
1 -74.2 Tyr70, Asp72, Trp84, Tyr121 
2 -93.8 Tyr70, Asp72, Trp84, Tyr121, Trp279, Tyr334 
3 -82.2 Trp84, Tyr121, Tyr70, Asp72 
4 -90.7 Trp84, Tyr121, Asp72, Trp279, Tyr334 
5 -89.6 Trp84, Tyr121, Tyr70, Trp279, Tyr334 
6 -93.2 Trp84, Tyr121, Tyr70, Trp279, Tyr334 
7 -105.6 Trp84, Tyr121, Asp72, Trp279, Tyr334 
8 -90.8 Trp84, Tyr121, Asp72, Trp279, Tyr334 
9 -114.9 Trp84, Tyr121, Tyr70, Asp72, Trp279, Tyr334 
10 -112.8 Trp84, Tyr121, Tyr70, Asp72, Trp279, Tyr334 
11 -104.4 Trp84, Tyr121, Tyr70, Asp72, Trp279, Tyr334 
12 -108.9 Trp84, Tyr121, Tyr70, Asp72, Trp279, Tyr334 
13 -99.3 Trp84, Tyr121, Tyr70, Asp72, Trp279, Tyr334 
14 -112.4 Trp84, Tyr121, Tyr70, Asp72, Trp279, Tyr334 
15 -90.5 Trp84, Tyr121, Tyr70, Asp72, Trp279, Tyr334 
16 -91.9 Trp84, Tyr121, Tyr70, Asp72, Trp279 
17 -91.3 Trp84, Tyr121, Tyr70, Asp72, Trp279, Tyr334 
18 -91.4 Trp84, Tyr121, Asp72, Trp279, Tyr334 
19 -86.1 Trp84, Tyr121, Trp279, Tyr334 
20 -88.5 Trp84, Tyr121, Tyr70, Trp279, Tyr334 
21 -101.3 Trp84, Tyr121, Tyr70, Asp72, Trp279, Tyr334 




Figure 3 — Interaction of residues with active site (PAS). 
Donepezil (purple color) and compound with minimum energy 
(compound no 9) is shown in yellow color 




synthesized compounds indicating their binding to 
PAS. Although, compound 9 is predicted to be most 
active by docking studies but it is less potent  
in the experimental in vitro activity determination. 
Experimentally compounds 3, 4 and 17 were found to 





Melting points reported are uncorrected. Synthetic 
procedures employed were monitored for completion 
as well as purity of product by Thin Layer 
Chromatography (TLC) employing 7 cm×2.5 cm 
Silica gel 60 F254 precoated TLC plates by Merck. 
Nuclear Magnetic Resonance Spectra were recorded 
on BrukerAvance DPX-200 (400 MHz). In 1H NMR 
chemical shifts (δ) are reported in parts per million 
(ppm) using tetramethylsilane as internal standard. 
Coupling constants (J) are reported in Hz (Hertz). 
Multiplicities are reported using the following 
abbreviations: s = singlet, d = doublet, t = triplet,  
q = quartet, m =multiplet, dd = double doublet. Mass 
Spectra were recorded on a Bruker Esquire 3000_00037. 
IR spectra were measured on a Hitachi 270-30 infrared 
and Bruker Vector 22 Spectrophotometers. IR spectra 
were recorded as KBr pellets. 
 
General procedure for the synthesis of 
tetrahydrocarbazole 
Refluxing of phenylhydrazine and cyclohexanone 
in glacial acetic acid for 5 min, leads the conversion 
of cyclohexanone into phenylhydrazone, without its 
isolation, (Scheme I) being converted into 2,3,4,9-
tetrahydrocarbazole. The solid was filtered in vacuo 
and recrystallized with ethanol instantly12,13. 
 
General procedure for the nitration of 
tetrahydrocarbazole, 2 
To a solution of sodium nitrate (1.70 g, 0.0200M ) 
in concentrated sulphuric acid (50 mL) (H2SO4), was 
added drop wise with stirring, over a period of 1h, a 
solution of 2,3,4,9-tetrahdrocarbazole (3.18g, 0.0200 
M) in 25 mL of concentrated sulphuric acid(H2SO4) 
and keep at 5°C in an ice bath. The solution was 
stirred for an additional 5 min and then poured onto 
crushed ice. The crude product was recrystallized 
from methylene chloride-petroleum ether (1:1). The 
orange yellowish blunt needles of the pure 6-nitro-
2,3,4,9-tetrahydrocarbazole 2 were obtained as 
crystals14. 
 
General procedure for the reduction of nitro-
2,3,4,9-tetrahydrocarbazole, 3 
To a 30 mL solution of ethanol 95% containing 
sodium hydroxide (3.6 mL, 20%), was added to 
compound 2 (1g) and dissolved. The mixture was 
heated to boiling in a two necked round bottom flask 
fitted with condenser. The source of heating was 
removed and zinc dust (2.9 g, 44.61mM) was added 
in portions to keep the solution boiling. After 
complete addition, the refluxing was continued for 1h 
until the solution became transparent. Hot mixture 
was filtered at pump; zinc residue returned to flask 
and extracted with three 20 mL portions of hot 
rectified spirit. The extracts were recombined, 2 g of 
sodium dithionite (Na2S2O4) was added and solvent 
was removed under pressure using rotary evaporator. 
The dried solid was washed with 20 mL of diethyl 
ether twice. The product was recrystallized from 
ethanol giving 6-amino-2,3,4,9-tetrahydrocarbazole 3 
as brownish red crystals15. 
 
General procedure for preparation of sulphonyl 
derivatives 
To 0.4 g (1.16 mM) of compound 2 and 3 in 3 mL 
dry pyridine, 0.267g (2.33 mM) of methane sulphonyl 
chloride, benzene sulphonyl chloride and tosyl 
chloride were added in small proportions and resultant 
mixture was heated to boiling for 30 min. After 
completion of the reaction, the reaction mixture was 
acidified with 2M HCl and poured on crushed ice. 
Precipitated product was filtered and washed well 
with water. The product was recrystallized using 
ethanol to yield compounds 11, 12, 13, 19, 20 16. 
 
General procedure for coupling reactions 
To a solution of 0.4 g (1.16 mM) of compound 2 
and 3, 1.74 mM of alkyl halides in 4 mL N,N-
dimethylformamide, potassium carbonate (0.2g) was 
added and refluxed for 24 h. The mixture was poured 
on crushed ice. The products were recrystallized with 
ethanol to yield compounds 4-10, 14-18, 21 and 22 17. 
 
2,3,4,9-Tetrahydro-1H-carbazole, 1: Yield 88%. 
m.p.118°C. IR (KBr): 3397, 3049, 2927, 1645, 1619, 
1233, 737 cm−1; 1H NMR (400MHz, DMSO-d6): δ 
8.14 (s, 1H, N-H)*, 7.42 (d, 1H, Ar H), 7.32 (dd, J= 
8.2, 2.4 Hz, 1H,Ar H), 7.15 (dd, J= 10.6, 2.4 Hz, 1H, 
Ar H), 7.05 (d,J= 2.4Hz, 1H, Ar H), 2.67 (t, J= 6.2, 
2H, Aliphatic H), 2.60 (t, J= 6.2, 2H, Aliphatic H), 
1.85-1.78 (m, 4H, Aliphatic H); MS (ESI): 172.03 
[M+1]; Mass calcd for C12NH13 171.10 [m/z]. 
 




6-Nitro-2,3,4,9-tetrahydro-1H-carbazole, 2: Yield 
80%. m.p.157°C. IR (KBr): 3373, 3046, 2933, 1630, 
1516 and 1324, 1473, 754 cm−1; 1H NMR (400MHz, 
DMSO-d6): δ 8.41 (d, J=2.1, 1H, N-H), 8.23 (s, 1H, 
Ar H), 8.03 (s, J= 7.3, 2.1 Hz, 1H,Ar H), 7.26 (d,  
J= 7.2, 1H, Ar H), 2.74-2.68 (m, 4H, Aliphatic H), 
1.92-1.79 (m, 4H,Aliphatic H); MS (ESI): 217.05 
[M+1]; Mass calcd for C12H12N2O2 216.09 [m/z]. 
 
6-Amino-2,3,4,9-tetrahydro-1H-carbazole, 3: Yield 
74%. m.p.134°C. IR (KBr): 3389 and 3214, 2917, 
1420, 1325, 735, 686 cm−1; 1H NMR (400MHz, 
DMSO-d6): δ 7.4 (s, 1H, N-H)*, 7.28 (s, 2H, N-H)*, 
7.01 (d, 1H, Ar H), 6.77 (d, 1H,Ar H), 6.57 (s, 1H, Ar 
H), 2.71-2.43 (m, 4H, Aliphatic H), 1.92-1.90 (m, 4H, 
Aliphatic H); MS (ESI): 187.04 [M+1]; Mass calcd 
for C12H14N2 186.11 [m/z]. 
 
9-Methyl-6-nitro-2,3,4,9-tetrahydro-1H-carbazole, 
4: Yield 71%. m.p.104°C. IR (KBr): 3048, 2921, 
1625, 1536 and 1318, 1473, 870, 689 cm−1; 1H NMR 
(400MHz, DMSO-d6): δ 7.03 (d, J = 8.36 Hz, 1H, Ar 
H), 6.82 (d, J = 2.25 Hz, 1H, Ar H), 6.64 (s, 1H, Ar 
H), 3.60 (s, 3H, N-CH3), 2.78 (t, 2H, Aliphatic H), 
2.52 (t, 2H, Aliphatic H), 1.90-1.78 (m, 4H, Aliphatic 
H); MS (ESI): 231.08 [M+1]; Mass calcd for 
C13H14N2O2 230.10 [m/z]. 
 
9-Ethyl-6-nitro-2,3,4,9-tetrahydro-1H-carbazole, 5: 
Yield 64%. m.p.110°C. IR (KBr): 3041, 2917, 1634, 
1528and 1310, 1469, 890, 672 cm−1; 1H NMR 
(400MHz, DMSO-d6): δ 7.26 (d, J = 8.36 Hz, 1H,Ar 
H), 6.77 (d, J = 2.25 Hz, 1H,Ar H), 6.57 (s, 1H, Ar 
H), 3.89 (q, 2H, N--CH2), 2.59 (t, 2H,Aliphatic H), 
2.49 (t, 2H,Aliphatic H), 1.56-1.47 (m, 4H, Aliphatic 
H), 1.43 (t, 3H, N-CH3); MS (ESI): 245.10 [M+1]; 
Mass calcd for C14H16N2O2 244.11 [m/z]. 
 
9-Propyl-6-nitro-2,3,4,9-tetrahydro-1H-carbazole, 6: 
Yield 46%. m.p.121°C. IR (KBr): 3048, 2924, 1625, 
1516 and 1324, 1473, 870, 686 cm−1; 1H NMR 
(400MHz, DMSO-d6): δ 7.18 (d, J = 8.36 Hz, 1H, Ar 
H), 6.83 (d, J = 2.25 Hz, 1H,Ar H), 6.69 (s, 1H,Ar H), 
3.78 (t, 2H, N--CH2), 2.66 (t, 2H, Aliphatic H), 2.35 
(t, 2H, Aliphatic H), 1.56-1.42 (m, 4H, Aliphatic H), 
1.81-1.76 (m, 2H, N-CH2), 0.96 (t, 3H, N-CH3); MS 




Yield 71%. m.p.115°C. IR (KBr): 3048, 2921, 1625, 
1516 and 1324, 1473, 870, 686 cm−1; 1H NMR 
(400MHz, DMSO-d6): δ 7.48 (d, J = 6.1 Hz, 1H, Ar 
H), 6.97 (d, J = 2.4 Hz, 1H,Ar H), 6.74 (s, 1H,Ar H), 
3.76 (t, 2H, N--CH2), 2.48 (t, 2H, Aliphatic H), 2.31 
(t, 2H, Aliphatic H), 1.77-1.69 (m, 2H, N--CH2), 1.51-
1.43 (m, 4H, Aliphatic H), 1.33-1.25 (m, 2H, N--
CH2), 0.83 (t, 3H, N-CH3); MS (ESI): 273.12 [M+1]; 
Exact mass calcd for C16H20N2O2272.15 [m/z]. 
 
9-Pentyl-6-nitro-2,3,4,9-tetrahydro-1H-carbazole, 8: 
Yield 55%. m.p.127°C. IR (KBr): 3048, 2921, 1625, 
1516 and 1324, 1473, 870, 686 cm−1; 1H NMR 
(400MHz, DMSO-d6): δ 7.92 (d, J = 8.36 Hz, 1H, Ar 
H), 6.99 (d, J = 2.5 Hz, 1H, Ar H), 6.83 (s, 1H, Ar H), 
3.85 (t, 2H, N-CH2), 2.68 (t, 2H, Aliphatic H), 2.53  
(t, 2H, Aliphatic H), 1.86-1.80 (m, 2H, N-CH2), 1.62-
1.53 (m, 4H,Aliphatic H), 1.48-1.41 (m, 2H, N-CH2), 
1.29-1.24 (m, 2H, N-CH2), 0.99 (t, 3H, N-CH3);  




Yield 68%. m.p.135°C. IR (KBr): 3048, 2921, 1625, 
1516 and 1324, 1473, 870, 686 cm−1; 1H NMR 
(400MHz, DMSO-d6): δ 8.20 (d, J = 6.1 Hz, 1H,Ar 
H), 7.26 (s, 1H, Ar H), 6.89 (d, J = 2.4 Hz, 1H, Ar H), 
3.79 (t, 2H, N-CH2), 2.52 (t, 2H, Aliphatic H), 2.48  
(t, 2H, Aliphatic H), 1.81-1.75 (m, 2H, N--CH2), 1.48-
1.36 (m, 4H, Aliphatic H), 1.21-1.17 (m, 2H, N-CH2), 
1.19-1.13 (m, 2H, N--CH2), 1.08-1.02 (m, 2H,N--
CH2), 0.83 (t, 3H, N-CH3); MS (ESI): 301.16 [M+1]; 
Mass calcd for C18H24N2O2300.18 [m/z]. 
 
9-Heptyl-6-nitro-2,3,4,9-tetrahydro-1H-carbazole, 
10: Yield 58%. m.p.142°C. IR (KBr): 3048, 2921, 
1625, 1516 and 1324, 1473, 870, 686 cm−1; 1H NMR 
(400MHz, DMSO-d6): δ 9.32 (d, J = 6.1 Hz, 1H,Ar 
H), 7.89 (s, 1H, Ar H), 6.64 (d, J = 2.4 Hz, 1H, Ar H), 
4.37 (t, 2H, H), 2.96 (t, 2H, Aliphatic H), 2.72 (t, 2H, 
Aliphatic H), 1.96-1.88 (m, 2H, N-CH2), 1.74-1.58 
(m, 4H, Aliphatic H), 1.42-1.37 (m, 2H, N-CH2), 
1.29-1.18 (m, 2H, N-CH2), 1.09-1.02 (m, 2H, N-CH2), 
0.92-0.85 (m, 2H, N--CH2), 0.68 (t, 3H, N-CH3); MS 




tetrahydro-1H-carbazole, 11: Yield 65%. 
m.p.162°C. IR (KBr): 3048, 2921, 1625, 1517 and 
1373, 1473, 1321 and 1155, 1124, 870, 686, 667 and 
614 cm−1; 1H NMR (400MHz, DMSO-d6): δ 9.82 (d, J 
= 3.2 Hz, 2H, Ar-Ts H), 8.85 (d,J = 4.7 Hz, 2H, Ar-Ts 
H), 7.89 (s, 1H, Ar H), 7.53 (d, J = 5.1 Hz, 1H, Ar H), 
7.31 (d, J = 2.1 Hz, 1H,Ar H), 2.9 (t, 2H, Aliphatic 




H), 2.58 (t, 2H, Aliphatic H), 2.28 (s, 3H, Ar-Ts-
CH3), 1.56-1.34 (m, 4H, Aliphatic H); MS (ESI): 




carbazole, 12: Yield 54%. m.p.123°C. IR (KBr): 
2976, 2817, 1621, 1508 and 1416, 1386, 1085 and 
1017, 1226, 870, 786, 667 and 614 cm−1; 1H NMR 
(400MHz, DMSO-d6): δ 7.96 (s, 1H, Ar H), 7.62 (d,  
J = 5.1Hz, 1H, Ar H), 6.35 (d, J = 2.1Hz, 1H, Ar H), 
2.59 (s, 3H, Ms-CH3), 2.54 (t, 2H, Aliphatic H), 2.27 
(t, 2H, Aliphatic H), 1.09-0.82 (m, 4H, Aliphatic H); 
MS (ESI): 295.02 [M+1]; Mass calcd for 
C13H14N2O4S 294.07 [m/z]. 
 
6-Nitro-9-(phenylsulfonyl)-2,3,4,9-tetrahydro-1H-
carbazole, 13: Yield 45%. m.p.143°C. IR (KBr): 
3058, 2912, 1658, 1518 and 1463, 1341, 1324 and 
1017, 1143, 870, 749, 648 and 618 cm−1; 1H NMR 
(400MHz, DMSO-d6): δ 7.90 (d, J = 6.7 Hz, 
2.1Hz,2H, Ar-Bs H), 7.54 (d, 2H, Ar-Bs H), 7.30 (t, 
1H, Ar-Bs H), 7.23 (s, 1H, Ar H), 7.05 (d, J = 8.35 
Hz, 1H,Ar H), 6.77 (d, J = 2.8 Hz, 1H, Ar H), 2.59 (t, 
2H, Aliphatic H), 2.43 (t, 2H, Aliphatic H), 1.01-0.80 
(m, 4H, Aliphatic H); MS (ESI): 357.07 [M+1]; Mass 
calcd for C18H16N2O4S356.08 [m/z]. 
 
9-Benzyl-6-nitro-2,3,4,9-tetrahydro-1H-carbazole, 
14: Yield 35%. m.p.122°C. IR (KBr): 3026, 2917, 
1607, 1591 and 1481, 1162, 870, 762 cm−1; 1H NMR 
(400MHz, DMSO-d6): δ 7.41 (s, 1H, Ar H), 7.34 (dd, 
J = 7.4 Hz, 2.2 Hz, 2H, Bz-Ar H), 7.23 (d, J = 8.35 
Hz, 1H,Ar H), 7.13 (t, 1H, Bz-Ar H), 7.02 (dd, J = 3.2 
Hz, 2H,Bz-Ar H), 6.82 (d, J = 2.3 Hz, 1H,Ar H), 5.21 
(s, 2H, Bz-CH2), 2.94 (t, 2H,Aliphatic H), 2.72 (t, 2H, 
Aliphatic H), 1.58-1.43 (m, 4H, Aliphatic H); MS 




Yield 64%. m.p.110°C. IR (KBr):3406, 2966, 1629, 
1595, 1349 cm−1; 1H NMR (400MHz, DMSO-d6):  
δ 8.45 (s, 1H, Ar-NH H)*, 7.50 (d, J = 8.12 Hz, 1H, 
Ar H), 6.90 (d, J = 8.14 Hz, 1H, Ar H), 6.75 (dd, J = 
2.12 Hz, Ar 1H,), 3.02 (s, 1H, Indole-NH)*, 2.84-2.78 
(m, 2H, CH2), 2.59 (q, 4H, Aliphatic H), 2.16 (q, 4H, 
Aliphatic H), 1.25 (t, 3H, CH3); MS (ESI): 215.12 
[M+1]; Mass calcd for C14H18N2214.15 [m/z]. 
 
N-Propyl-2,3,4,9-tetrahydro-1H-carbazol-6-amine, 
16: Yield 46%. m.p.121°C. IR (KBr):3406, 2966, 
1629, 1595, 1349 cm−1; 1H NMR (400MHz, DMSO-
d6): δ 8.6 (s, 1H, Ar-NH ), 7.01 (d, J = 8.10 Hz, 1H, 
Ar H), 6.82 (d, J = 8.14 Hz, 1H,Ar H), 6.68 (dd,  
J = 2.32 Hz, 1H, Ar H), 3.31 (s, 1H,Indole-NH), 3.14 
(m, 4H, Aliphatic H and CH2 ), 2.98 (t,2H, CH2), 
1.64-1.48 (m, 6H, Aliphatic H), 1.02 (t, 3H, CH3);  




17: Yield 71%. m.p.115°C. IR (KBr):3042, 2924, 
1631, 1595, 1349, 673 cm−1; 1H NMR (400MHz, 
DMSO-d6): δ 8.07 (s, 1H, Ar-NH H), 7.49 (d, J = 8.22 
Hz, 1H, Ar H), 6.95 (d, J = 8.24 Hz, 1H,Ar H), 6.80 
(dd, J = 2.23 Hz, 1H, Ar H), 3.48 (s, 1H, Indole-NH), 
3.23 (q, 2H, CH2), 2.81 (m, 4H, Aliphatic H), 1.67-
1.56 (m, 4H, Aliphatic H), 1.43-1.35 (m, 4H, 2CH2), 
0.92 (t, 3H, CH3); MS (ESI): 243.15 [M+1]; Exact 
mass calcd for C16H22N2242.18 [m/z]. 
 
N-Pentyl-2,3,4,9-tetrahydro-1H-carbazol-6-amine, 
18: Yield 55%. m.p.127°C. IR (KBr):3014, 2966, 
1618, 1582, 1337, 664 cm−1; 1H NMR (400MHz, 
DMSO-d6): δ 7.68 (s, 1H, Ar-NH), 7.14 (d, J = 8.48 
Hz, 1H,Ar H), 6.63 (d, J = 8.41 Hz, 1H, Ar H), 6.75 
(dd, J = 2.50 Hz, 1H, Ar H), 3.43 (s, 1H,Indole-NH), 
3.08 (q, 2H,CH2), 2.58-2.49 (m, 4H, Aliphatic H), 
2.16-2.03 (m, 4H, Aliphatic H), 1.98-1.92 (m, 2H, 
CH2), 1.37-1.23 (m, 4H, 2CH2), 1.25 (t, 3H, CH3); 




benzenesulfonamide, 19: Yield 65%. m.p.162°C. IR 
(KBr): 3373, 2918, 1321 and 1155, 659 and 614 cm−1; 
1H NMR (400MHz, DMSO-d6): δ 8.27 (s, 1H, Ar-
NH), 7.57 (d, J = 7.24 Hz, 2H,Ar-Ts H), 7.21-7.14 
(m, 3H,Ar and Ar-Ts H), 7.03 (d, J = 2.35 Hz, 1H,Ar 
H), 6.78 (dd, J = 8.46, 2.35 Hz, 1H,Ar H), 4.20  
(s, 1H,,Indole-NH), 2.78 (t, 2H,Aliphatic H), 2.60  
(t, 2H,Aliphatic H), 2.19 (s, 3H, CH3), 1.91-1.79  
(m, 4H, Aliphatic H); MS (ESI): 341.09 [M+1]; Mass 
calcd for C19H20N2O2S340.12 [m/z]. 
 
N-(2,3,4,9-Tetrahydro-1H-carbazol-6-yl) 
methanesulfonamide, 20: Yield 54%. m.p.123°C. IR 
(KBr): 3217, 2786, 1364 and 1128, 657 and 604 cm−1; 
1H NMR (400MHz, DMSO-d6): δ 8.9 (s, 1H, Ar-NH), 
7.36 (d, J = 8.46 Hz, 1H, Ar H), 7.11 (d, J = 8.36 Hz, 
1H,Ar H), 6.9 (dd, J = 2.46 Hz, 1H,Ar H), 3.12  
(s, 1H, Indole-NH), 2.84 (s, 3H,CH3), 2.74 (t, 2H, 
Aliphatic H), 2.66 (t, 2H, Aliphatic H), 1.25-1.14  
(m, 4H, Aliphatic H); MS (ESI): 265.03 [M+1]; Mass 
calcd for C13H16N2O2S264.08 [m/z]. 





21: Yield 45%. m.p.143°C. IR (KBr): 3258, 1646, 
1474, 1319, 1136, 798 cm−1; 1H NMR (400MHz, 
DMSO-d6): δ 8.80 (s, 1H,Ar-NH H), 8.23 (s, 1H, 
Indole-NH), 7.82 (dd, J = 7.28 Hz, 2H, Benzoyl H), 
7.22-7.15 (m, 4H, Benzoyl H and Ar H), 7.11  
(s, 1H, Ar H), 7.04 (d, J = 8.26 Hz, 1H, Ar H), 2.66-2.60 
(m, 2H, Aliphatic H), 2.54-2.48 (m, 2H, Aliphatic H), 
1.25-1.15 (m, 4H, Aliphatic H); MS (ESI): 291.13 
[M+1]; Mass calcd for C19H18N2O290.14 [m/z]. 
 
N-Benzyl-2,3,4,9-tetrahydro-1H-carbazol-6-amine, 
22: Yield 35%. m.p.122°C. IR (KBr): 3394, 2811, 
1573, 1350, 1108, 798 cm−1; 1H NMR (400MHz, 
DMSO-d6): δ 8.01 (s, 1H, Ar-NH), 7.45-7.28 (m, 5H, 
Benzyl H), 7.01 (d, J = 7.46 Hz, 1H), 6.59 (d, J = 7.47 
Hz, 1H, Ar H), 6.50 (dd, J = 2.21 Hz, 1H, Ar H), 3.56 
(s, 2H,Benzyl H), 3.21 (s, 1H,Indole-NH), 2.94-2.81 
(m, 4H, Aliphatic H), 1.22-1.07 (m, 4H, Aliphatic H); 
MS (ESI): 276.11 [M+1]; Mass calcd for C18H20 
N2276.15 [m/z]. 
* Disappeared in D2O exchange 
 
Biological Activity 
The experimental protocol was approved by 
Institutional Animal Ethics committee (IAEC) and 
care of animals were taken as per guidelines of 
committee for the purpose of control and supervision 
of Experiment on animals (CPCSEA), Ministry of 
Environment and Forest Government of India, (Reg. 
No. 107/1999/CPCSEA). 
The 2,3,4,9-tetrahydrocarbazole derivatives (from 
1 to 22) were synthesized and evaluated for their 
biological activity as acetylcholinestrase inhibitors to 
be used as possible Anti-Alzheimer drug candidates, 
by employing an in-vitro acetylcholinesterase assay 
on brain tissue of swiss albino mice, based on the 
colorimetric Acetylcholinesterase assay method 
developed by Ellman. The results are summarized in 
Table I and compared to Donepezil. 
 
Assay for AChE and BChE inhibitory activity 
Miceacetylcholinesterasewas obtained frombrain 
and butyrylcholinesterasefrom serum. The AChE 
activity was measured by the method of 
Ellmanspectrophotometric method with slight 
modification18,19. This was measured on basis of the 
formation of yellow color due to the reaction of 
thiocholine with dithiobisnitrobenzoate ions. The rate 
of formation of thiocholine from Acetylthiocholine 
Iodide in the presence of cholinesterase was  
measured using a spectrophotometer. 0.5 mL of clear 
supernatant liquid of the brain homogenate was 
pipetted out into 25 mL volumetric flask and dilution 
was made with a freshly prepared 5,5'-Dithiobis-(2-
nitrobenzoic acid) (DTNB) solution (10 mg DTNB in 
100 mL of Sorenson phosphate buffer, pH 8.0). From 
the volumetric flask, two 4 mL portions were pipetted 
out into test tubes. Into one of the test tube, 2 drops of 
donepezil solution was added. 1 mL of substrate 
solution (75 mg of Acetylthiocholine iodide per 50 
mL of distilled water or 75 mg of Butyrylthiocholine 
iodide per 50 mL of distilled water) was pipetted out 
into both of the test tubes. The test tube containing 
donepezil was taken as blank and the absorbance of 
the test sample was read spectrophotometrically  
(DU 640B spectrophotometer, Beckman Coulter Inc., 
CA, USA) at 420 nm and IC50values have been 
calculated. All experiments have been performed in 
triplicate. 
 
Docking and Screening 
In order to carry out docking simulations, 
iGEMDOCK was used as molecular docking tool. 
iGEMDOCK is an accurate and validated software 
based on GEMDOCK which uses a genetic 
evolutionary method for molecular docking and an 
empirical scoring function21. The crystal structure of 
Torpedo californica acetylcholinesterase (1EVE) was 
retrived from PDB (www.rscb.org)11. The defined 
binding site was set to ‘By bounded ligand’ and 
standard parameters were set automatically by the 
software. The binding site center (Ligand name) was 
set to E20. Binding site radius was adjusted to 20A° 
including ‘retain reference ligand’. Different 
compounds were prepared using ChemSketch 
software. After that structure was cleaned and explicit 
hydrogens were added. Finally structure was 
optimised to 3D so that it can be used in 
iGEMDOCK. At the end structure was saved in MDL 
MolFile [V2000, (*.mol)] format. All the ligands 
were loaded in iGEMDOCK software and GA 
parameters were set. Default setting was set to 
standard docking; where population size, generation 
and no of solution were 200, 70 and 2 respectively. 
Output path was set and then docking was started. 
After completion of docking, ‘view docked pose and 
post analysis’ was done. Under interaction profile, 
energy of each compound was obtained and under 
interaction analysis interacting residues were 
obtained. The results were viewed in ‘Molegro 
Molecular Viewer’ software. 





In the present investigations 2,3,4,9-tetrahydro-1H-
carbazole and its derivatives were designedby 
substitution at 6 and 9 position as selective 
acetylcholinesterase inhibitors. These derivatives 
were tested by Ellman’s method for the estimation of 
acetylcholinesterase and butyrylcholinesterase 
inhibitory activity. All compounds were found to 




(compound 17) were found to be selective AChE 
inhibitors. Hence, Compounds 3, 4 and 17 can be 
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